Keywords: sb, avandia, leading, class, usa, smithkline, beecham

SB's Avandia "leading the class" in the USA

Article | 13 January 2000

Print This

SmithKline Beecham says that its antidiabetic drug Avandia(rosiglitazone) has passed the one million prescription mark, after seven months on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in